InvestorsHub Logo
Post# of 251541
Next 10
Followers 826
Posts 119439
Boards Moderated 16
Alias Born 09/05/2002

Re: DewDiligence post# 236061

Wednesday, 06/09/2021 11:42:03 AM

Wednesday, June 09, 2021 11:42:03 AM

Post# of 251541
FDA approves PFE’s Prevnar-20 pneumococcal_vaccine_for_adults:

Prevnar-20 is PFE’s enhancement to Prevnar-13 — with protection for 7 additional serotypes that account for about 40% of serious pneumococcal infections. Prevnar-13 has been PFE’s biggest-selling product,* doing $5.9B in 2020 sales. The Prevnar-20 pediatric program has its own set of clinical trials, with an expected BLA submission in 2022.

Meanwhile, MRK is trying to compete in the adult and pediatric pneumococcal-vaccine markets with V114, a 15-serotype. V114 for adults is under FDA review with a PDUFA date in Jul 2021. MRK expects a BLA submission for the pediatric market in late 2021.

Prevnar-20 would seem to have an insurmountable edge versus V114 due to coverage of 5 additional serotypes; however, the commercial success of both vaccines will depend greatly on the recommendations of the CDC’s ACIP committee. ACIP is scheduled to convene in Oct 2021 to make recommendations vis-à-vis the adult market.

PFE recently started a trial to co-administer (but not co-formulate) Prevnar-20 and PFE’s COVID-19 vaccine (#msg-163985031). Although Prevnar has no efficacy against COVID per se, it protects against secondary bacterial pneumonia infections that are the proximal cause of many COVID-related deaths.

*Eliquis is a bigger-selling drug, but Eliquis revenues are split between PFE and BMY.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.